Mr Potter with Dr Gareth Gregory in the MHTP Clinical Trials Centre |
A novel therapy for aggressive lymphoma
is being tested in a world-first clinical trial at the Monash Health
Translation Precinct (MHTP).
In early 2015, researchers at Monash
University and Peter MacCallum Cancer Centre showed the novel anti-lymphoma
therapy is remarkably effective against one of the most aggressive B-cell
lymphomas in animal models.
Mr George Potter is the first
aggressive B-cell lymphoma patient in Australia—and only second in the world—to
receive the new treatment, a drug called dinaciclib, a type of
epigenetic therapy that can alter the way a cancer cell reads its own abnormal
DNA.
"Certain B-cell lymphomas depend
on a cancer causing gene called ‘Myc',” said lead researcher and Monash Health
haematologist Dr Gareth Gregory.
"Patients with aggressive lymphoma
usually respond well to initial chemotherapy.
Unfortunately, those that relapse or are resistant to upfront therapy have
a poor response to further therapies and ultimately have a poor
prognosis."
"In the case of aggressive
lymphoma, dinaciclib effectively
turns off genes that Myc is activating and then kills the cells, including
those resistant to conventional chemotherapy," said Dr Gregory.
Dr Gregory and Head of Haematology
Research at the School of Clinical Sciences at Monash Health (SCS) Associate
Professor Jake Shortt have worked on this type of lymphoma for more than seven
years and have tested numerous novel and conventional therapies.
"In animal models, dinaciclib is
the most effective treatment we have seen to date by a long way," said Associate
Professor Shortt.
"We've even seen results in animal
models that have led to some cures—this is something we have never seen
before."
Mr Potter is receiving his treatment at
the newly opened Clinical Trials Centre at MHTP.
“I am thrilled and very grateful to be
part of this trial,” said Mr Potter.
Dr Gregory said initial results from
the clinical trial will be available after two to three months of treatment,
but overall assessment will take approximately two years.
“We are quite hopeful this therapy will
prolong life and provide durable remissions,” added Dr Gregory.
Lymphomas are the most common form of
haematological or blood cancer in Australia, and the sixth most common form of
cancer overall. The incidence of
lymphomas has more than doubled over the past 20 years and is continuing to
rise, for no known reason.